Once the deal is closed, Elanco would obtain a portfolio of about 50 marketed animal-health products. As part of the proposed agreement, Janssen animal-health employees solely dedicated to the animal-health business will transfer to Elanco. No manufacturing facilities would be included in the transaction. Closing of the transaction is contingent upon European regulatory authorities’ clearance plus it is subject to other customary closing conditions. Other terms of the transaction were not disclosed.
Adding Janssen’s animal-health business will strongly support a number of strategic growth priorities for Elanco, while providing synergies with that company’s current operations, said Jeff Simmons, Lilly senior vice president and president of Elanco.
“Through this transaction, we intend to further expand our European presence, bolster our growing portfolio of companion-animal medicines and diversify our food-animal portfolio with new swine and poultry products,” he added.